Valmet receives the eighth tissue line order from Hayat Kimya
Valmet Oy’s press release on July 22, 2020 at 11:00 a.m. EET
Valmet will supply the eighth tissue line delivery including an extensive automation package to Turkish tissue producer Hayat Kimya. The company has decided to invest in a third machine in Russia in order to meet the increasing demand for their high-quality tissue products. This is the first machine at their new mill outside Moscow. The new line will add 70,000 tons of tissue to company’s current production of facial, toilet and towel tissues.
The order is included in Valmet’s orders received of the second quarter 2020. The value of the order will not be disclosed.
Hayat Kimya, the current world speed record holder with their TM2 tissue machine in Turkey supplied by Valmet, is constantly targeting latest technology to reach the highest efficiency and the lowest possible energy consumption. Previously the company has installed six Valmet Advantage DCT 200TS tissue production lines to its mills in Turkey, Russia and Egypt with one more starting-up in 2021.
“Our ambition is to run at high efficiency and Valmet’s technology is certainly supporting that target. We are regularly updating our machine fleet to make sure we always operate at optimum production level. We find both Valmet’s technology and people easy to deal with,” says Lütfi Aydin, Director, Paper Group, Hayat Kimya.
“We are excited to be part of Hayat Kimya’s successful journey. The company started only fourteen years ago and is already a world player, who will soon have nine tissue lines in operation,” says Björn Magnus, Sales Director, Tissue Mills business unit, Paper business line, Valmet.
Valmet Advantage DCT 200 TS tissue machine
The new tissue machine TM9 will have a width of 5.6 m and a design speed of 2,200 m/min.
The raw material to be used in the tissue production will be virgin fiber. The new production line is optimized to save energy and to enhance the quality of the final product.
Valmet’s scope of delivery will comprise a complete tissue production line featuring stock preparation systems and a Valmet Advantage DCT 200 TS tissue machine. The machine will be equipped with an OptiFlo headbox and a cast alloy Yankee cylinder. It will also be featured with the Advantage tissue technology including ViscoNip press, an AirCap Heli hood and air system prepared for co-generation, WetDust dust system, sheet transfer system and a SoftReel L reel. The line also includes a Valmet F(O)CUS Rewinder. The stock preparation line will consist of OptiSlush pulpers, OptiFiner conical refiners and OptiScreen machine screens.
Furthermore, the delivery will include an extensive Valmet automation package with Valmet DNA machine controls, process controls and Valmet IQ quality controls. Complete engineering, installation supervision, training, start-up and commissioning are also included in the delivery.
Information about Hayat Kimya
Hayat Kimya A.S. is part of the Hayat Group. The Hayat Group primarily operates in the home care, hygiene and tissue categories for the consumer goods industry. Hayat has continued to invest significantly since their entrance into the tissue category 14 years ago and today the Group carries "The Largest Tissue Manufacturer of Africa, Middle East and Eastern Europe" title with 490,000 tonnes production capacity/year.
Further information, please contact:
Jan Erikson, Vice President, Sales, Tissue Mills business unit, Paper business line, Valmet, tel. +46 70 517 14 90
Björn Magnus, Sales Director, Tissue Mills business unit, Paper business line, Valmet, tel. +46 703 17 79 83
Valmet is the leading global developer and supplier of process technologies, automation and services for the pulp, paper and energy industries. We aim to become the global champion in serving our customers.
Valmet's strong technology offering includes pulp mills, tissue, board and paper production lines, as well as power plants for bioenergy production. Our advanced services and automation solutions improve the reliability and performance of our customers' processes and enhance the effective utilization of raw materials and energy.
Valmet's net sales in 2019 were approximately EUR 3.5 billion. Our more than 13,000 professionals around the world work close to our customers and are committed to moving our customers' performance forward - every day. Valmet's head office is in Espoo, Finland and its shares are listed on the Nasdaq Helsinki.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Saniona announces outcome of warrant exercise23.9.2020 19:00:00 CEST | Press release
PRESS RELEASE September 23, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, announced today the outcome in the exercise of warrants of series TO 2, that was issued in connection with Saniona’s rights issue and directed issue in the first quarter of 2020. During the period September 7 – 21, 2020, holders of warrants of series TO 2 had the right to subscribe for new shares, by exercise of warrants. In total, 1,329,141 warrants of series TO 2 were exercised, corresponding to a subscription rate of approx. 90 percent. Saniona will thereby receive proceeds of approx. SEK 33.2 million (USD 3.6 million), before issue costs, which amount to approx. SEK 0.4 million. Number of shares and share capital Saniona will receive proceeds of approx. SEK 33.2 million, before issue costs. Issue costs amount to approx. SEK 0.4 million. When the new shares have been registered with the Swedish Companies Registration Office (“Bolagsverket”), the total number o
Saniona meddelar utfall i optionsinlösen23.9.2020 19:00:00 CEST | Pressemelding
PRESSMEDDELANDE 23 september 2020 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelade idag utfallet i inlösen av teckningsoptioner av serie TO 2, vilka emitterades i samband med Sanionas företrädesemission och riktade emission under det första kvartalet 2020. Under perioden 7 – 21 september 2020 har innehavare av teckningsoptioner av serie TO 2 kunnat teckna aktier med stöd av teckningsoptioner. Totalt nyttjades 1 329 141 teckningsoptioner av serie TO 2, vilket motsvarar en nyttjandegrad om cirka 90 procent. Saniona tillförs därmed cirka 33,2 MSEK (3,6 MUSD) före emissionskostnader, vilka beräknas uppgå till cirka 0,4 MSEK. Antal aktier och aktiekapital Saniona tillförs cirka 33,2 MSEK före emissionskostnader. Emissionskostnaderna beräknas uppgå till cirka 0,4 MSEK. När de nya aktierna har registrerats hos Bolagsverket kommer antalet aktier i Saniona uppgå till 62 372 831 stycken och aktiekapitalet uppgå till 3 118 641,
Auction details treasury bills23.9.2020 16:20:00 CEST | Press release
Auction date September 30, 2020 Maturity date Issue volume, SEK million Days (Act/360) ISIN code 2021-01-20 15,000 110 SE0014957866 Settlement date October 2, 2020 Bids have to be entered by 11.00 on September 30, 2020 Bid only through dealers approved by the Swedish National Debt Office For more information, please contact: The funding desk + 46 8 613 4780 Fo@riksgalden.se
SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING23.9.2020 16:20:00 CEST | Press release
SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING 2020-09-25 Transaction type:SEK CreditTender date:2020-09-25Time for submission of bids:10.30-11.00 (CEST)Payment date:2020-09-29Final repayment date2024-09-30Offered volume:50 billion SEKMinimum bid amount:10 million SEKMaximum bid amount:12.5 billion SEKMaximum number of bids from each participant: 1Interest rate:0.00 %Additional interest rate:0.10 per cent ALL APPROVED COUNTERPARTIES ARE INVITED TO SUBMIT VOLUME BIDS TO THE RIKSBANK (46-8-6966970) BY 11.00 ON SEPTEMBER 25 2020, AT THE LATEST. CONFIRMATION ON E-MAIL: email@example.com Result of the auction will be published at 11.30 (CEST) on Tender date. Complete terms and conditions can be retrieved at http://www.riksbank.se
Cypress Development to Collaborate on Lithium Research Projects23.9.2020 14:00:10 CEST | Press release
VANCOUVER, British Columbia, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Cypress Development Corp. (TSX-V:CYP) (OTCQB:CYDVF) (Frankfurt:C1Z1) (“Cypress” or “the Company”), developer of a world class lithium claystone deposit in Nevada, announced today, the Company, as an industrial partner with several high tech research entities, has been encouraged along with its partners in full project proposal submissions to the Department of Energy (DOE), Office of Energy Efficiency and Renewable Energy (EERE). This has culminated in the recent formal submittal of two lithium project proposals for research to be conducted over the next three years. The first project is in collaboration with the University of Utah, Colorado School of Mines, and Cornell University, and is titled "Highly Selective Resource Independent Lithium Extraction Processes." This technology will demonstrate the use of Next Generation Lithium Ion Sieve Technology (NGLIST) as an innovative and low-impact processing method for recovering
Nordic American Tankers Ltd (NYSE: NAT) – NAT orders two -2- Suezmax newbuildings in South Korea23.9.2020 11:54:47 CEST | Press release
September 23, 2020 Dear Shareholders and Investors, We wish to announce that NAT has entered into two -2- suezmax newbuilding contracts in South Korea, increasing our fleet of suezmaxes to 25 units. The combination of specifications, quality of yard, price, payment terms and deliveries make this an attractive investment for NAT and is consistent with our strategy to expand and renew our fleet. The scheduled deliveries of the ships are in the first half of 2022. Through the years we have enjoyed an excellent relationship with the shipbuilding sector in South Korea, and we are happy to conclude further suezmax newbuilding contracts with Samsung Heavy Industries Ltd. NAT will consider various financing alternatives prior to deliveries. The payment terms of the newbuildings are 10/10/10/10 with 60% of the building price on deliveries. The two first instalments of the vessels have already been funded. The main focus of NAT is always to pay quarterly dividends, which we have done every singl